Clinical Scorecard: Residual Risk Assessment via Imaging Following Left Atrial Appendage Occlusion: Implications for Device Monitoring and Antithrombotic Therapy Decisions

At a Glance

Key Highlights

• Device-related thrombus (DRT) has an event rate of ischemic stroke of 6.3 per 100 patient-years.
• Hypoattenuated thickening (HAT) varies from expected healing to thrombus-like abnormalities.
• CCTA detects residual appendage patency and peri-device leak more frequently than TEE.
• Post-LAAO imaging should focus on risk-weighted interpretation rather than binary surveillance.
• Management implications are primarily based on expert consensus and observational evidence.

Guideline-Based Recommendations

Diagnosis

• Use multimodality imaging to assess device position and detect DRT.

Management

• Consider adjunctive antithrombotic therapy based on imaging findings.

Monitoring & Follow-up

• Regular imaging surveillance is necessary to evaluate device performance and residual risks.

Risks

• Persistent uncertainty in the clinical actionability of imaging findings.

Patient & Prescribing Data

Patients with nonvalvular atrial fibrillation at high bleeding risk or with contraindications to anticoagulation.

Management decisions should be informed by imaging-defined residual risks.

Clinical Best Practices

• Standardize imaging acquisition and interpretation protocols.
• Utilize TEE for real-time assessment in selected cases.
• Integrate evidence from randomized trials, registry data, and expert consensus in decision-making.

Related Resources & Content

• Clinical Trials and Registries
• Multimodality Imaging Reviews